Drugs

, Volume 59, Supplement 4, pp 9–17 | Cite as

Clinical Perspectives on Platinum Resistance

  • Giuseppe Giaccone
Review Article

Abstract

The platinum compounds cisplatin and carboplatin are widely used in the treatment of a number of solid malignancies. Although some platinum-sensitive tumours may be cured by combination chemotherapy (e.g. testicular cancer), most will relapse and subsequently prove resistant to platinum compounds. The mechanisms of platinum resistance in patients are still poorly understood. Clearly, when a tumour relapses a long time after successful first-line treatment, there is a high chance that it will still be sensitive to platinum compounds. A number of studies have attempted to assess the role of drug transport, the glutathione system, DNA repair and apoptosis genes in the development of resistance in tumours, but no conclusive evidence is available. Approaches to increasing the potency of platinum therapy (to overcome resistance) have been devised and some have proved to be effective; in particular, intraperitoneal administration of cisplatin has shown superiority over intravenous administration in selected patients with ovarian cancer. The development of drugs and techniques to reduce the adverse effects of platinum chemotherapy has greatly improved their administration. Investigations attempting to modulate platinum activity and toxicity have also been performed.

Further investigation of in vivo resistance mechanisms should be valuable in allowing prediction of clinical response to chemotherapy and may identify new treatments with the potential to improve outcomes for patients with a variety of platinum-resistant tumour types.

References

  1. 1.
    Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59 Suppl. 4: 1–8PubMedCrossRefGoogle Scholar
  2. 2.
    Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000; 59 Suppl. 4: 29–36PubMedCrossRefGoogle Scholar
  3. 3.
    Jassem J. Chemotherapy of advanced non-small cell lung cancer. Ann Oncol 1999; 10: S77–82CrossRefGoogle Scholar
  4. 4.
    Johnson DH. Management of small cell lung cancer. Current state of the art. Chest 1999; 116: S525–30CrossRefGoogle Scholar
  5. 5.
    Zöchbauer-Müller S, Pirker R, Huber H. Treatment of small cell lung cancer patients. Ann Oncol 1999; 10: S83–91CrossRefGoogle Scholar
  6. 6.
    McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340–8PubMedGoogle Scholar
  7. 7.
    Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25: 199–206PubMedCrossRefGoogle Scholar
  8. 8.
    Thigpen T. Second-line therapy for ovarian carcinoma: general concepts. American Society of Clinical Oncology 1999 Educational Book; Atlanta, 1999Google Scholar
  9. 9.
    Chen G, Hutter KJ, Zeller WJ. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 1995; 11: 273–81PubMedCrossRefGoogle Scholar
  10. 10.
    Muggia FM, Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells 1993: 11; 182–93PubMedCrossRefGoogle Scholar
  11. 11.
    Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10(4): 513–4PubMedGoogle Scholar
  12. 12.
    Giaccone G. Identification of new drugs in pretreated patients with small cell lung cancer. Eur J Cancer Clin Oncol 1989; 25: 411–3PubMedCrossRefGoogle Scholar
  13. 13.
    Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264–70PubMedGoogle Scholar
  14. 14.
    Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small cell lung cancer: long term results of a randomized trial. J Clin Oncol 1993; 11: 1230–40PubMedGoogle Scholar
  15. 15.
    Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990; 8: 1613–7PubMedGoogle Scholar
  16. 16.
    Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070–4PubMedCrossRefGoogle Scholar
  17. 17.
    O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosemberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott Publishers, 1997: 418–32Google Scholar
  18. 18.
    Izquierdo MA, Scheffer GL, Flens MJ, et al. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996; 19: 191–7PubMedCrossRefGoogle Scholar
  19. 19.
    Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230–7PubMedCrossRefGoogle Scholar
  20. 20.
    Uchiumi T, Hinoshita E, Haga S, et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistantcancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 1998; 252: 103–10PubMedCrossRefGoogle Scholar
  21. 21.
    Britten RA, Green JA, Warenius HM. Cellular glutathione (GSH) and glutathione-S-transferases (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 1992; 64: 527–31CrossRefGoogle Scholar
  22. 22.
    Ali-Osmon F, Berger MS, Rairkar A, et al. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem 1994; 54: 11–9CrossRefGoogle Scholar
  23. 23.
    Reed E, Ozols RF, Tarone R, et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84; 5024–8PubMedCrossRefGoogle Scholar
  24. 24.
    Ma J, Verweij J, Planting ASTL, et al. Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and DNA repair. BrJ Cancer 1995;71: 512–7CrossRefGoogle Scholar
  25. 25.
    Schellens JHM, Ma J, Planting ASTL, et al. Relationship between the exposure to cisplatin, DNA adduct formation in leukocytes, and tumor response in patients with solid tumors. Br J Cancer 1996; 73: 1569–75PubMedCrossRefGoogle Scholar
  26. 26.
    Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331–44PubMedCrossRefGoogle Scholar
  27. 27.
    Dabholkar M, Viommet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703–8PubMedCrossRefGoogle Scholar
  28. 28.
    Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309–16PubMedGoogle Scholar
  29. 29.
    Dabholkar M, Berger MS, Vionnet JA, et al. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995; 55: 1261–6PubMedGoogle Scholar
  30. 30.
    Crul M, Schellens JHM, Beijnen JH, et al. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997; 23: 341–66PubMedCrossRefGoogle Scholar
  31. 31.
    Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087–90PubMedGoogle Scholar
  32. 32.
    Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1–6PubMedGoogle Scholar
  33. 33.
    Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45–52PubMedCrossRefGoogle Scholar
  34. 34.
    Ferreira CG, Tolis C, Giaccone G. P53 and chemosensitivity. Ann Oncol 1999; 10: 1011–21PubMedCrossRefGoogle Scholar
  35. 35.
    Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1995; 55: 1649–54Google Scholar
  36. 36.
    Kaye SB, Paul J, Cassidy J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329–33PubMedCrossRefGoogle Scholar
  37. 37.
    Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14(7): 2113–9Google Scholar
  38. 38.
    Nichols CR, Williams SD, Loehrer PJ, et al. Cisplatin doseintensity in testicular cancer treatment: analysis of a randomized clinical trial. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991: 409–20Google Scholar
  39. 39.
    Wandt H, Birkmann J, Denzel T, et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/TI study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763–70PubMedCrossRefGoogle Scholar
  40. 40.
    Hirai T, Korogi Y, Hamatake S, et al. Stages III and IV squamous cell carcinoma of the mouth: three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Cardiovasc Intervent Radiol 1999; 22: 201–5PubMedCrossRefGoogle Scholar
  41. 41.
    Shami J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution: studies with intra-arterial Pt-195mcisplatin in humans. Cancer Res 1989; 49: 1877–81Google Scholar
  42. 42.
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950–5PubMedCrossRefGoogle Scholar
  43. 43.
    Gabizon A. Tailoring liposomes for cancer drug delivery: from the bench to the clinic. AnnBiol Clin (Paris) 1993; 51: 811–3Google Scholar
  44. 44.
    Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1–7PubMedCrossRefGoogle Scholar
  45. 45.
    Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990; 265: 11285–8PubMedGoogle Scholar
  46. 46.
    Manetta A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. Gynecol Oncol 1998; 68(1): 45–6PubMedCrossRefGoogle Scholar
  47. 47.
    Lertratanangkoon K, Savaraj N, Scimeca JM, et al. Glutathione depletion-induced thymidylate insufficiency for DNA repair synthesis. Biochem Biophys Res Commun 1997; 19: 470–5CrossRefGoogle Scholar
  48. 48.
    Lai G-M, Ozols RF, Young RC, et al. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol 1989; 37: 4597–600CrossRefGoogle Scholar
  49. 49.
    Calvert P, Yao KS, Hamilton TC, et al. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998 Apr 24: 111–2, 213–24Google Scholar
  50. 50.
    O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59 Suppl. 4: 19–27PubMedCrossRefGoogle Scholar
  51. 51.
    Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cisdiamminedichloroplatinum with synthetic thiosulfate protection. Cancer Res 1983; 43: 1426–31PubMedGoogle Scholar
  52. 52.
    Lebwohl D, Canetta R. Clinial development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522–34PubMedCrossRefGoogle Scholar
  53. 53.
    Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535–42PubMedCrossRefGoogle Scholar
  54. 54.
    Crino L, Scagliotti GV, Marangolo M, et al. Cisplatingemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297–303PubMedGoogle Scholar
  55. 55.
    Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatin against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575–80PubMedGoogle Scholar
  56. 56.
    Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659–71PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Giuseppe Giaccone
    • 1
  1. 1.Department of Medical OncologyAcademic Hospital Vrije UniversiteitAmsterdamThe Netherlands

Personalised recommendations